Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange. He says although typically one is supposed to sell biotech stocks here, he believes the group has gotten under-owned. He likes two speculative biotech names, Receptos (RCPT) and Radius Health (RDUS), as well as the four horsemen, which are Biogen (BIIB), Gilead (GILD), Celgene (CELG) and Regeneron (REGN). In terms of the IT industry, Cramer says he believes Cognizant's (CTSH) multiple is too low and it's going higher. He also stresses that Facebook (FB) continues to deliver on every metric and the stock has gotten too cheap. He recommends owning it instead of trading it. Send in your questions for Jim on Twitter (TWTR) using #CramerQ.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.